Literature DB >> 34205397

Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies.

Violaine Randrian1,2, Camille Evrard3, David Tougeron1,2.   

Abstract

A defect in the DNA repair system through a deficient mismatch repair system (dMMR) leads to microsatellite instability (MSI). Microsatellites are located in both coding and non-coding sequences and dMMR/MSI tumors are associated with a high mutation burden. Some of these mutations occur in coding sequences and lead to the production of neo-antigens able to trigger an anti-tumoral immune response. This explains why non-metastatic MSI tumors are associated with high immune infiltrates and good prognosis. Metastatic MSI tumors result from tumor escape to the immune system and are associated with poor prognosis and chemoresistance. Consequently, immune checkpoint inhibitors (ICI) are highly effective and have recently been approved in dMMR/MSI metastatic colorectal cancers (mCRC). Nevertheless, some patients with dMMR/MSI mCRC have primary or secondary resistance to ICI. This review details carcinogenesis and the mechanisms through which MSI can activate the immune system. After which, we discuss mechanistic hypotheses in an attempt to explain primary and secondary resistances to ICI and emerging strategies being developed to overcome this phenomenon by targeting other immune checkpoints or through vaccination and modification of microbiota.

Entities:  

Keywords:  colorectal cancer; deficient mismatch repair; immune checkpoint inhibitor; immunotherapy; microbiota; microsatellite instability

Year:  2021        PMID: 34205397     DOI: 10.3390/cancers13123063

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  7 in total

Review 1.  Immune Checkpoint Inhibitors in Cancer Therapy.

Authors:  Yavar Shiravand; Faezeh Khodadadi; Seyyed Mohammad Amin Kashani; Seyed Reza Hosseini-Fard; Shadi Hosseini; Habib Sadeghirad; Rahul Ladwa; Ken O'Byrne; Arutha Kulasinghe
Journal:  Curr Oncol       Date:  2022-04-24       Impact factor: 3.109

2.  Distinct Hypoxia-Related Gene Profiling Characterizes Clinicopathological Features and Immune Status of Mismatch Repair-Deficient Colon Cancer.

Authors:  Yixin Xu; Junjie Hu; Can Cao; Mili Zhang; Youdong Liu; Haonan Chen; ShanShan Wei; Ziyan Zhu; Yuqin Yang; Liang Yu; Jikun Li
Journal:  J Oncol       Date:  2021-12-07       Impact factor: 4.375

3.  Serum Untargeted UHPLC-HRMS-Based Lipidomics to Discover the Potential Biomarker of Colorectal Advanced Adenoma.

Authors:  Yifan Zhu; Lisheng Wang; Yanying Nong; Yunxiao Liang; Zongsheng Huang; Pingchuan Zhu; Qisong Zhang
Journal:  Cancer Manag Res       Date:  2021-11-26       Impact factor: 3.989

4.  UHPLC-HRMS-based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer.

Authors:  Hongwei Chen; Jiahao Zhang; Hailin Zhou; Yifan Zhu; Yunxiao Liang; Pingchuan Zhu; Qisong Zhang
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

5.  RNA editing facilitates the enhanced production of neoantigens during the simultaneous administration of oxaliplatin and radiotherapy in colorectal cancer.

Authors:  Yasuhiro Komatsu; Kunitoshi Shigeyasu; Shuya Yano; Sho Takeda; Kazutaka Takahashi; Nanako Hata; Hibiki Umeda; Kazuhiro Yoshida; Yoshiko Mori; Kazuya Yasui; Ryuichi Yoshida; Yoshitaka Kondo; Hiroyuki Kishimoto; Fuminori Teraishi; Yuzo Umeda; Shunsuke Kagawa; Hiroyuki Michiue; Hiroshi Tazawa; Ajay Goel; Toshiyoshi Fujiwara
Journal:  Sci Rep       Date:  2022-08-08       Impact factor: 4.996

6.  Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer.

Authors:  Quang Loc Bui; Léo Mas; Antoine Hollebecque; David Tougeron; Christelle de la Fouchardière; Thomas Pudlarz; Emily Alouani; Rosine Guimbaud; Julien Taieb; Thierry André; Raphaël Colle; Romain Cohen
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

Review 7.  Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors.

Authors:  Xin Zhang; Huiqin Li; Xiupeng Lv; Li Hu; Wen Li; Meiting Zi; Yonghan He
Journal:  Life (Basel)       Date:  2022-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.